{"nctId":"NCT01242241","briefTitle":"Propofol in Obese Children","startDateStruct":{"date":"2008-04-01","type":"ACTUAL"},"conditions":["Pharmacodynamics","Obesity"],"count":80,"armGroups":[{"label":"Non-obese","type":"OTHER","interventionNames":["Drug: Propofol"]},{"label":"Obese children","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Propofol"]}],"interventions":[{"name":"Propofol","otherNames":["Diprivan"]},{"name":"Propofol","otherNames":["Diprivan"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Children between the ages of 3 and 17 years who fall into the categories of non-obese(BMI percentile between 25-84th percentile) or obese(\\>95th percentile)\n2. American Society of Anesthesiology(ASA) classification 1 or 2-\n\nExclusion Criteria:\n\n1. Patients classified as ASA (American Society of Anesthesiology) Class 3 or greater.\n2. Patients with documented kidney or liver disease or those presenting for open surgery on the liver or kidney.\n3. Patients who will NOT be receiving propofol for induction as part of their anesthetic regimen.\n4. Patients who are currently on anti-convulsant medication or receiving drugs with sedative effects.\n5. Patients currently being treated for attention deficit disorder.\n6. Patients who are diagnosed with failure to thrive or those with a BMI less than 25th percentile.\n7. Patients who are hemodynamically unstable.\n8. Patients with egg allergy.\n9. Patients with low levels of albumin -","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Dose of Propofol That Caused Loss of Consciousness in 95% (ED95) of Obese and Non-obese Children","description":"Propofol is administered over 10 seconds. 20 seconds after adminstration, loss of consciousness is assessed by the presence or absence of a lash reflex. The dose responsible for loss of lash reflex/consciousness in 95% of patients was determined in mg/kg.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2.125","spread":null}]}]}]},{"type":"SECONDARY","title":"Depth of Sedation","description":"After propofol administration, the patient was assessed for depth of sedation at 30 seconds, 1 minute, and 2 minutes using the University of Michigan Sedation Scale (UMSS) and Ramsay Sedation Scale. UMSS assesses the level of alertness on a five-point scale ranging from 1 (wide awake) to 5 (unarousable with deep stimulation). Ramsay Sedation Scale assesses the level of sedation on a six-point scale ranging from 1 (Patient is anxious and agitated or restless, or both) to 6 (Patient exhibits no response).","paramType":"MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.65","spread":null},{"groupId":"OG001","value":"3.57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.86","spread":null},{"groupId":"OG001","value":"3.73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.82","spread":null},{"groupId":"OG001","value":"3.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.74","spread":null},{"groupId":"OG001","value":"5.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.92","spread":null},{"groupId":"OG001","value":"5.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.92","spread":null},{"groupId":"OG001","value":"5.86","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":40},"commonTop":[]}}}